CUSIP 00032Q104 · who reports it, how much, and how much it matters to them
15 of the 720 hedge fund managers we track reported shares of Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) on Form 13F for 30 June 2026. Between them they reported USD 86m. The largest position belongs to Acuta Capital Partners, at USD 21m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Acuta Capital Partners2 funds on PPLI.com | USD 21m | 15.0% |
| 2 | Suvretta Capital Management4 funds on PPLI.com | USD 20m | 0.4% |
| 3 | Orbimed Advisors1 fund on PPLI.com | USD 18m | 0.3% |
| 4 | Avoro Capital Advisors1 fund on PPLI.com | USD 13m | 0.1% |
| 5 | Ally Bridge Group (Ny)3 funds on PPLI.com | USD 3.7m | 3.3% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 1.9m | 0.0% |
| 7 | Millennium Management6 funds on PPLI.com | USD 1.7m | 0.0% |
| 8 | Eversept Partners3 funds on PPLI.com | USD 1.4m | 0.1% |
| 9 | Verdad Advisers6 funds on PPLI.com | USD 1.4m | 1.3% |
| 10 | Two Sigma Investments35 funds on PPLI.com | USD 1.4m | 0.0% |
| 11 | Balyasny Asset Management25 funds on PPLI.com | USD 1.3m | 0.0% |
| 12 | POINT72 Asset Management17 funds on PPLI.com | USD 262,000 | 0.0% |
| 13 | Citadel Advisors32 funds on PPLI.com | USD 138,000 | 0.0% |
| 14 | Scientech Research2 funds on PPLI.com | USD 49,638 | 0.0% |
| 15 | The Quarry1 fund on PPLI.com | USD 998 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Acuta Capital Partners | USD 21m | 15.0% |
| 2 | Ally Bridge Group (Ny) | USD 3.7m | 3.3% |
| 3 | Verdad Advisers | USD 1.4m | 1.3% |
| 4 | Suvretta Capital Management | USD 20m | 0.4% |
| 5 | Orbimed Advisors | USD 18m | 0.3% |
| 6 | Avoro Capital Advisors | USD 13m | 0.1% |
| 7 | Eversept Partners | USD 1.4m | 0.1% |
| 8 | Scientech Research | USD 49,638 | 0.0% |
| 9 | Renaissance Technologies | USD 1.9m | 0.0% |
| 10 | Balyasny Asset Management | USD 1.3m | 0.0% |
Whitehawk Therapeutics, Inc. trades under the symbol WHWK on the Nasdaq. Its CUSIP, the code used on Form 13F, is 00032Q104.
15 of the 720 hedge fund managers PPLI.com tracks reported Whitehawk Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Acuta Capital Partners (USD 21m), Suvretta Capital Management (USD 20m), Orbimed Advisors (USD 18m), Avoro Capital Advisors (USD 13m) and Ally Bridge Group (Ny) (USD 3.7m).
15 managers in our coverage reported it, and between them they run 151 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Acuta Capital Partners, where the position was 15.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Whitehawk Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.